<div id="readability-page-1"><p>Donald L. Hagan LLC purchased a new position in shares of  Bristol Myers Squibb Company (NYSE:BMY - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 20,550 shares of the biopharmaceutical company's stock, valued at approximately $927,000.</p><ul><li>Why GRAIL Stock Could Be Biotech’s Next Big Breakout</li></ul><p>Other large investors also recently made changes to their positions in the company. Brighton Jones LLC increased its stake in shares of  Bristol Myers Squibb by 33.4% during the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company's stock worth $1,116,000 after purchasing an additional 4,935 shares during the last quarter.  Jump Financial LLC bought a new position in  Bristol Myers Squibb during the first quarter worth about $438,000.  Ieq Capital LLC increased its position in  Bristol Myers Squibb by 27.6% during the first quarter. Ieq Capital LLC now owns 172,523 shares of the biopharmaceutical company's stock worth $10,522,000 after buying an additional 37,362 shares during the last quarter.  CreativeOne Wealth LLC raised its stake in  Bristol Myers Squibb by 6.4% in the first quarter. CreativeOne Wealth LLC now owns 32,748 shares of the biopharmaceutical company's stock valued at $1,997,000 after buying an additional 1,969 shares during the period.  Finally, Transamerica Financial Advisors LLC lifted its position in shares of  Bristol Myers Squibb by 1.0% in the first quarter. Transamerica Financial Advisors LLC now owns 24,065 shares of the biopharmaceutical company's stock valued at $1,468,000 after buying an additional 241 shares during the last quarter. Institutional investors and hedge funds own  76.41% of the company's stock. </p><div><p><span></span><span>Get <strong>Bristol Myers Squibb</strong> alerts:</span></p></div><h2>Bristol Myers Squibb Stock Performance</h2><p>NYSE BMY opened at $54.63 on Friday. The firm has a 50-day moving average price of $48.61 and a two-hundred day moving average price of $47.33. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $63.33. The company has a market capitalization of $111.20 billion, a P/E ratio of 18.45, a P/E/G ratio of 8.37 and a beta of 0.29. The company has a quick ratio of 1.17, a current ratio of 1.27 and a debt-to-equity ratio of 2.39. </p><ul><li>Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet</li></ul><p>Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 EPS for the quarter, topping the consensus estimate of $1.52 by $0.11. The company had revenue of $12.22 billion for the quarter, compared to analysts' expectations of $11.75 billion. Bristol Myers Squibb had a net margin of 12.57% and a return on equity of 76.53%. The business's revenue for the quarter was up 2.8% on a year-over-year basis. During the same period last year, the firm earned $1.80 earnings per share. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS.  Analysts anticipate that  Bristol Myers Squibb Company will post 6.74 earnings per share for the current year. </p><h2>Bristol Myers Squibb Increases Dividend</h2><p>The business also recently announced a quarterly dividend, which will be paid on Monday, February 2nd. Stockholders of record on Friday, January 2nd will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.6%. The ex-dividend date is Friday, January 2nd. This is a positive change from Bristol Myers Squibb's previous quarterly dividend of $0.62. Bristol Myers Squibb's dividend payout ratio  is currently 83.78%. </p><h2>Analysts Set New Price Targets</h2><ul><li>MarketBeat Week in Review – 02/03 - 02/07</li></ul><p>A number of research analysts recently weighed in on the company. Sanford C. Bernstein  reissued a &#34;market perform&#34; rating on shares of Bristol Myers Squibb in a report on Monday, November 3rd. Wall Street Zen upgraded shares of Bristol Myers Squibb from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a report on Saturday, November 8th. Guggenheim  restated a &#34;buy&#34; rating on shares of Bristol Myers Squibb in a research note on Tuesday. Weiss Ratings  reaffirmed a &#34;hold (c-)&#34; rating on shares of Bristol Myers Squibb in a report on Tuesday, October 14th. Finally, BMO Capital Markets  reissued a &#34;market perform&#34; rating on shares of Bristol Myers Squibb in a report on Monday, November 17th. Six equities research analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and one  has assigned  a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of &#34;Hold&#34; and an average target price of $54.62.</p><p><b>Read Our Latest Stock Report on Bristol Myers Squibb</b></p><h2>Bristol Myers Squibb Company Profile</h2> (Free Report)<p>Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.  </p><p>BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Bristol Myers Squibb</li><li>Turn your &#34;dead money&#34; into $306+ monthly (starting this month)</li><li>Washington prepares for war</li><li>Put $1,000 into this stock by Jan 1 [Not NVDA]</li><li>The McDonald's Secret</li><li>33,000% boom from weird new “AI Fuel?”</li></ul><p><strong>Want to see what other hedge funds are holding BMY?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Bristol Myers Squibb Right Now?</h2><p>Before you consider Bristol Myers Squibb, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol Myers Squibb wasn't on the list.</p><p>While Bristol Myers Squibb currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Donald L. Hagan LLC acquired 20,550 shares of Bristol Myers Squibb Company, valued at approximately $927,000, during the 3rd quarter. Other investors, including Brighton Jones LLC and Ieq Capital LLC, also adjusted their positions in the company. Bristol Myers Squibb reported a quarterly EPS of $1.63, surpassing estimates, and announced a dividend increase to $0.63 per share. Analysts have mixed ratings on the stock, with an average rating of 'Hold' and a target price of $54.62.</p>

Donald L. Hagan LLC Purchases Shares of 20,550 Bristol Myers Squibb Company $BMY